AVIR FY 2024 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$83M

Operating Income

-$193M

Net Income

-$168M

EPS (Diluted)

$-2.00

Cash Flow

Operating Cash Flow

-$135M

Free Cash Flow

-$135M

Stock-Based Comp.

$52M

Balance Sheet

Total Assets

$465M

Total Liabilities

$26M

Stockholders' Equity

$439M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$83M	-$70M	-18.9%
Operating Income	-$193M	-$164M	-17.5%
Net Income	-$168M	-$136M	-23.9%